Analys av Danske Bank efter delårsrapport kvartal 2, 2020

Handling the crisis well

Although the COVID-19 outbreak has (temporarily) held back Zenicor’s new s ale s and uncertainity is still high, the first month of Q3 offered an uptick in activity with a new large contract in the UK being signed. The majority of Ze nicor’s s ale s are recurring and the cost base has proven to be flexible, and we do not believe there should be any longterm negative effects once the pandemic crisis is over.

Click here to access the report